Studies have concluded that chatbots have the potential in treating mental health issues and could be used as an effective tool for delivering cognitive behavioral therapy.

The Canadian Down Syndrome Society (CDSS) is partnering with Dr. Dan Gordon and his research team from Anglia Ruskin University and with Dr. Michael Merzenich and his team from BrainHQ to launch a research study and awareness campaign to examine this potential link between physical fitness and mental fitness for people with Down syndrome.

The U.S. Federal Trade Commission (FTC) formed a multinational working group to evaluate pharmaceutical mergers.

New Covid-19 cases continue to decline in North America, but in Latin America infections are still rising, particularly in Brazil where a resurgence has caused record daily deaths, the Pan American Health Organization (PAHO) warned on March 10.

Confidence in Covid-19 vaccines is growing, with people’s willingness to have the shots increasing as they are rolled out across the world and concerns about possible side effects are fading, a 14-country survey showed on March 5.

The gout medication colchicine will be tested in a large UK study looking into potential early-stage Covid-19 treatments and enrollment criteria was widened for the latest arm of the trial, University of Oxford researchers said on March 3.

The World Health Organization listed AstraZeneca’s Covid-19 vaccine for emergency use, widening access in the developing world, while sources said the EU is in talks with Moderna on buying more vaccines.

Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.

Pfizer slashed in half the volume of Covid-19 vaccines the company will deliver to some EU countries this week, government officials said, as frustration over the U.S. drugmaker’s unexpected cut in supplies grows.

The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.